Largest-ever study on children’s soft contact lens safety shows low complication rates

Extensive retrospective review offers real-world data for myopia management in children

IMAGE

Credit: R Chalmers

SAN RAMON, Calif., December 10, 2020–The largest-ever retrospective study of its kind has found very low complication rates in children who wear soft contact lenses, similar to rates in adults.(1) The newly-published outcomes offer eye care professionals (ECPs) valuable real-world information to better counsel parents and caregivers as they consider proven myopia management options to help slow myopia progression.

Adverse Event Rates in The Retrospective Cohort Study of Safety of Paediatric Soft Contact Lens Wear: the ReCSS Study will appear in the January 2021 issue of Ophthalmic & Physiological Optics, the peer reviewed journal of the UK College of Optometrists. It is now available in pre-press form via open access.

Widely-respected independent researcher Robin Chalmers, OD, FAAO, served as principal investigator, co-authoring the paper with CooperVision scientists John McNally, OD, FAAO, and Paul Chamberlain, BSc(Hons), and Lisa Keay, PhD, Head of the School of Optometry and Vision Science for UNSW Sydney.

The work was initiated to support CooperVision’s regulatory submissions of MiSight® 1 day contact lenses, which are currently available in 26 countries with more expected in 2021.

ReCSS measured the rate of adverse events (AE) in children who were prescribed soft contact lenses before they turned 13 years old to establish wearing safety among that age group. The review documented AE details from clinical practice charts and clinical trial data of nearly 1,000 children and observed 2,713 years of wear across 4,611 visits. Compared to AE results derived exclusively from clinical trials, these data are likely to be more generalizable to real world experiences as myopia control soft contact lenses are prescribed more widely to young patients.

Clinical records from office visits with potential AEs were independently reviewed by an adjudication panel to determine a consensus diagnosis. The current findings are very similar to but slightly lower than rates reported in previous studies of similar age groups, possibly attributed to the higher proportion of daily disposable lenses in the current study. The study found the annualized incidence rate of inflammatory events was less than 1 percent per year of wear. The majority of events were conjunctivitis or foreign body abrasions, reflective of this young population.

The authors note that ReCSS study found a lower rate of microbial keratitis (7.4/10,000 years of wear) with a tighter confidence interval than other pediatric post?market studies, offering reassurance to clinicians and parents of children regarding the safety of myopia control soft contact lenses. That rate is comparable to established rates of microbial keratitis in adults. (2,3,4)

“ReCSS is the most extensive compilation of ‘real-world’ data supporting safety of soft contact lens wear in children, complementing the effectiveness research from our groundbreaking, multi-year MiSight® 1 day clinical study,” said McNally, who serves as CooperVision’s Senior Director of Clinical Research. “Practitioners will appreciate the fact that the study included a range of eyecare practice types and locations and a variety of soft contact lens brands, modalities and designs. Parents should be even more confident in embracing the benefits of a soft contact lens-based approach to myopia management by knowing that the study evaluated the safety of contact lenses in children of the same age range as their own.”

###

About CooperVision

CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit http://www.coopervision.com.

About CooperCompanies

CooperCompanies (“Cooper”) is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit http://www.coopercos.com.

(1) Chalmers, RL, McNally, JJ, Chamberlain, P, & Keay, L. Adverse event rates in the retrospective cohort study of safety of paediatric soft contact lens wear: the ReCSS study. Ophthalmic Physiol Opt. 2020.
https://doi.org/10.1111/opo.12753

(2) Poggio EC, Glynn RJ, Schein OD et al. The incidence of ulcerative keratitis among users of daily?wear and extended?wear soft contact lenses. N Engl J Med 1989; 321: 779-783.

(3) Stapleton F, Keay L, Edwards K et al. The incidence of contact lens related microbial keratitis. Ophthalmology 2008; 115: 1655-1662.

(4) Schein OD, McNally JJ, Katz J et al. The Incidence Of Microbial Keratitis among wearers of a 30?day silicone hydrogel extended?wear contact lens. Ophthalmology 2005; 112: 2172-2179.

Media Contact

Mike McDougall, APR,
Fellow PRSA,
McDougall Communications

[email protected]
or +1-585-434-2150

Media Contact
Mike McDougall
[email protected]

Related Journal Article

http://dx.doi.org/10.1111/opo.12753

Comments